Fig. 1.
Fig. 1. Effects of STI571 treatment on bone marrow fibrosis and megakaryocytes. / (A) Group 3 patient FM. Bone marrow biopsy before STI571 treatment showing marked fibrosis (grade 3). Gomori stain, × 400. (B) Same patient. Bone marrow biopsy after 3-month STI571 treatment without fibrosis (grade 0). Gomori stain, × 400. (C) Estimated dynamics of bone marrow fibrosis during therapy. 0 corresponds to absence of fibrosis. Error bars represent 95% confidence intervals. Estimates were obtained from a multivariate model and are bootstrap-corrected and adjusted for patient grouping. (D) Estimated dynamics of CD61+ megakaryocytes during therapy. Error bars represent 95% confidence intervals. Estimates were obtained from a multivariate model and are bootstrap-corrected and adjusted for patient grouping.

Effects of STI571 treatment on bone marrow fibrosis and megakaryocytes.

(A) Group 3 patient FM. Bone marrow biopsy before STI571 treatment showing marked fibrosis (grade 3). Gomori stain, × 400. (B) Same patient. Bone marrow biopsy after 3-month STI571 treatment without fibrosis (grade 0). Gomori stain, × 400. (C) Estimated dynamics of bone marrow fibrosis during therapy. 0 corresponds to absence of fibrosis. Error bars represent 95% confidence intervals. Estimates were obtained from a multivariate model and are bootstrap-corrected and adjusted for patient grouping. (D) Estimated dynamics of CD61+ megakaryocytes during therapy. Error bars represent 95% confidence intervals. Estimates were obtained from a multivariate model and are bootstrap-corrected and adjusted for patient grouping.

Close Modal

or Create an Account

Close Modal
Close Modal